Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs

International Journal of Cancer

Volumn 125, Issue 11, 2009, Pages 2586-2594

  Pradelli, Emmanuelle ^a,b   Karimdjee Soilihi, Babou ^a,b   Michiels, Jean François ^a,c   Ricci, Jean Ehrland ^a,d   Millet, Marie Ange ^a,b   Vandenbos, Fanny ^a,c   Sullivan, Timothy J ^e   Collins, Tassie L ^e   Johnson, Michael G ^e   Medina, Julio C ^e   Kleinerman, Eugenie S ^f   Schmid Alliana, Annie ^a,b   Schmid Antomarchi, Heidy ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c PASTEUR HOSPITAL   (France)

^d INSERM   (France)

^e AMGEN INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Animal models; Chemokine receptors; Lung metastasis; Osteosarcoma

Indexed keywords

AMG 487; CALCIUM; CASPASE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; CXCR3 PROTEIN, HUMAN; CXCR3 PROTEIN, MOUSE; N (1 (3 (4 ETHOXYPHENYL) 4 OXO 3,4 DIHYDROPYRIDO(2,3 D)PYRIMIDIN 2 YL)ETHYL) N PYRIDIN 3 YLMETHYL 2 (4 TRIFLUOROMETHOXYPHENYL)ACETAMIDE; N-(1-(3-(4-ETHOXYPHENYL)-4-OXO-3,4-DIHYDROPYRIDO(2,3-D)PYRIMIDIN-2-YL)ETHYL)-N-PYRIDIN-3-YLMETHYL-2-(4-TRIFLUOROMETHOXYPHENYL)ACETAMIDE; PYRIMIDINONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACETAMIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CASPASES; CELL MOVEMENT; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PYRIMIDINONES; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350707759     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24665     Document Type: Article

References (54)

1. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-1731 (Pubitemid 28129196)
2. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345:833-835 (Pubitemid 34940852)
3. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-179 (Pubitemid 38586742)
4. Makishima H, Ito T, Asano N, Nakazawa H, Shimodaira S, Kamijo Y, Nakazawa Y, Suzuki T, Kobayashi H, Kiyosawa K, Ishida F. Significance of chemokine receptor expression in aggressive NK cell leukemia. Leukemia 2005;19:1169-1174
5. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004;41:e59.
6. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-2567 (Pubitemid 40569454)
7. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56 (Pubitemid 32225831)
8. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008;25:201-211
9. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-8612 (Pubitemid 39552073)
10. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M, Taketo MM. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64:4010-4017 (Pubitemid 38697317)
11. Robledo MM, Bartolome RA, Longo N, Rodriguez-Frade JM, Mellado M, Longo I, van Muijen GN, Sanchez-Mateos P, Teixido J. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-45105 (Pubitemid 37391301)
12. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A. The expression of the chemokine receptor CXCR3 and its ligand. CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004;92:171-178
13. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life. Sci. 2006;78:1784-1793
14. Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A. Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005;29:105-117 (Pubitemid 40029606)
15. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000;95:627-632 (Pubitemid 30041679)
16. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006;66:7701-7707 (Pubitemid 44289229)
17. Wijtmans M, Verzijl D, Leurs R, de Esch IJ, Smit MJ. Towards small-molecule CXCR3 ligands with clinical potential. Chem Med Chem 2008;3:861-872
18. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000;18:261-271 (Pubitemid 32269996)
19. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999;17:501-506
20. Rezzonico R, Schmid-Alliana A, Romey G, Bourget-Ponzio I, Breuil V, Breittmayer V, Tartare-Deckert S, Rossi B, Schmid-Antomarchi H. Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells. J Bone Miner Res 2002;17:869-878
21. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-3759 (Pubitemid 32694989)
22. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004;279:51630-51646
23. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VDOPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003;8:345-352 (Pubitemid 36935206)
24. Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP, Auberger P. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J 2008;22:1894-1904 (Pubitemid 351811466)
25. Vitale S, Schmid-Alliana A, Breuil V, Pomeranz M, Millet MA, Rossi B, Schmid-Antomarchi H. Soluble fractalkine prevents monocyte chemoattractant protein-1-induced monocyte migration via inhibition of stress-activated protein kinase 2/p38 and matrix metalloproteinase activities. J Immunol 2004;172:585-592
26. Xie K, Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis 2003;20:31-43. (Pubitemid 36308134)
27. Mueller A. Internalization: what does it tell us about pharmacokinetic and pharmacodynamic properties of an antagonist? Br J Pharmacol 2007;152:1145-1146
28. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94:3658-3667
29. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516. (Pubitemid 33096184)
30. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174 (Pubitemid 37328786)
31. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992;31:7152-7154
32. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169:5546-5554 (Pubitemid 35291653)
33. Green DR. Apoptosis. Death deceiver. Nature 1998;396:629-630
34. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572 (Pubitemid 37328923)
35. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
36. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68 (Pubitemid 10098769)
37. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-228 (Pubitemid 27446075)
38. Fernandes T, de Angelo-Andrade LA, Morais SS, Pinto GA, Chagas CA, Maria-Engler SS, Zeferino LC. Stromal cells play a role in cervical cancer progression mediated by MMP-2 protein. Eur J Gynaecol Oncol 2008;29:341-344
39. O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 2008;409:635-649 (Pubitemid 351214190)
40. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J Biol Chem 2004;279:39513-39519 (Pubitemid 39258218)
41. Ogawa K, Chen F, Kuang C, Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappa B site. Biochem J 2004;381:413-422 (Pubitemid 38969685)
42. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T, Seiki M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. Embo J 2001;20:4782-4793 (Pubitemid 32848631)
43. Strongin AY, Marmer BL, Grant GA, Goldberg GI. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem 1993;268:14033-14039 (Pubitemid 23195520)
44. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008;25:345-356 (Pubitemid 351748979)
45. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Briere F, Trinchieri G, Caux C. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198:823-830
46. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927-932 (Pubitemid 28323558)
47. Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD81 T lymphocytes but not inhibition of angiogenesis. J Immunother 2005;28:343-351 (Pubitemid 40962327)
48. Katschke KJ, Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, Ponath P, Park CC, Pope RM, Koch AE. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44:1022-1032 (Pubitemid 32433606)
49. Penna G, Vulcano M, Sozzani S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol 2002;63:1164-1171 (Pubitemid 36025991)
50. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998;28:3696-3705 (Pubitemid 28510780)
51. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445
52. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008;68:8437-8445
53. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16:38-52. (Pubitemid 43139708)
54. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006;176:1517-1524 (Pubitemid 43134295)